Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Slow Release DHEA in Asthma
NCT05623059Phase 2Completed
- Sponsor
- Indiana University
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dehydroepiandrosterone in asthma, sponsored by Indiana University. Primary endpoints: Peak DHEA Concentration, Increase in DHEA-S in Blood Levels and 1 more. Started Mar 2023; status: completed.
02
Drugs
dehydroepiandrosterone
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05623059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623059.